Segment, Customer and Geographical Reporting (Tables)

6 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The Company’s segment information for the three months ended March 31, 2019 and 2018 is summarized below:

Results of Operations for the Three Months Ended March 31,
2019
	Optics			Innovation and Development*			Biomedical			Total
Revenue	$	6,226,000		$	5,306,000		$	-		$	11,532,000
Gross profit		2,159,000			2,199,000			-			4,358,000
GM %		35	%		41	%		-			38	%
Operating expenses		1,871,000			2,141,000			22,000			4,034,000
Operating income (loss)		288,000			58,000			(22,000	)		324,000
Depreciation and amortization		292,000			60,000			3,000			355,000
Capital expenditures		313,000			47,000			-			360,000
Intangibles, net		358,000			145,000			198,000			701,000
Goodwill		961,000			4,939,000			-			5,900,000
Total assets	$	21,482,000		$	9,456,000		$	204,000		$	31,142,000

Results of Operations for the Three Months Ended March 31,
2018
	Optics			Innovation and Development*			Biomedical			Total
Revenue	$	5,910,000		$	4,345,000		$	-		$	10,255,000
Gross profit		2,050,000			1,895,000			-			3,945,000
GM %		35	%		44	%		-			38	%
Operating expenses		1,858,000			1,813,000			194,000			3,865,000
Operating income (loss)		192,000			82,000			(194,000	)		80,000
Depreciation and amortization		247,000			61,000			3,000			311,000
Capital expenditures		339,000			58,000			29,000			426,000
Intangibles, net		455,000			179,000			363,000			997,000
Goodwill		1,070,000			4,939,000			-			6,009,000
Total assets	$	20,903,000		$	8,028,000		$	586,000		$	29,517,000

*Formerly Contract Research

The Company’s segment information for the six months ended March 31, 2019 and 2018 is summarized below:

Results of Operations for the Six Months Ended March 31,
2019
	Optics			Innovation and Development*			Biomedical			Total
Revenue	$	11,947,000		$	9,613,000		$	-		$	21,560,000
Gross profit		4,009,000			4,041,000			-			8,050,000
GM %		34	%		42	%		-			37	%
Operating expenses		3,756,000			4,020,000			75,000			7,851,000
Operating income (loss)		253,000			21,000			(75,000	)		199,000
Depreciation and amortization		566,000			120,000			7,000			693,000
Capital expenditures		497,000			64,000			-			561,000
Intangibles, net		358,000			145,000			198,000			701,000
Goodwill		961,000			4,939,000			-			5,900,000
Total assets	$	21,482,000		$	9,456,000		$	204,000		$	31,142,000

Results of Operations for the Six Months Ended March 31,
2018
	Optics			Innovation and Development*			Biomedical			Total
Revenue	$	10,853,000		$	8,590,000		$	-		$	19,443,000
Gross profit		3,740,000			3,745,000			-			7,485,000
GM %		34	%		44	%		-			38	%
Operating expenses		3,433,000			3,537,000			639,000			7,609,000
Operating income (loss)		307,000			208,000			(639,000	)		(124,000	)
Depreciation and amortization		477,000			126,000			7,000			610,000
Capital expenditures		928,000			77,000			45,000			1,050,000
Intangibles, net		455,000			179,000			363,000			997,000
Goodwill		1,070,000			4,939,000			-			6,009,000
Total assets	$	20,903,000		$	8,028,000		$	586,000		$	29,517,000

*Formerly Contract Research

Schedule Of Segment Revenue By Geographical Location [Table Text Block]

Revenue by geographic location in total and as a percentage of total revenue, for the three months ended March 31, 2019 and 2018 are as follows:

	Three Months Ended					Three Months Ended
	March 31, 2019					March 31, 2018
Geographic Location	Revenue		% of Total			Revenue		% of Total
United States	$	8,773,000		76	%	$	8,129,000		79	%
Asia		865,000		7	%		671,000		7	%
Europe		1,713,000		15	%		1,365,000		13	%
Other		181,000		2	%		90,000		1	%
	$	11,532,000		100	%	$	10,255,000		100	%

Revenue by geographic location in total and as a percentage of total revenue, for the six months ended March 31, 2019 and 2018 are as follows:

	Six Months Ended					Six Months Ended
	March 31, 2019					March 31, 2018
Geographic Location	Revenue		% of Total			Revenue		% of Total
United States	$	16,233,000		75	%	$	15,481,000		80	%
Asia		1,795,000		8	%		1,193,000		6	%
Europe		3,237,000		15	%		2,633,000		13	%
Other		295,000		2	%		136,000		1	%
	$	21,560,000		100	%	$	19,443,000		100	%